The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) decreased by -$0.23 on Monday to finish at $9.55, down -2.35 percent. The last five days have seen an average of 6,685,220 shares of common stock traded. 5 times new highs were reached in the current year, with a gain of $0.43. The average number of shares traded over the last 20 days was 11,161,210, while the average volume over the last 50 days totaled 11,802,304.
TEVA stock appreciated 16.32% since last month. On 07/18/23, the company’s shares reached a one-month low of $7.95. The stock touched a high of $11.44 on 01/12/23, after rallying from a low of $7.09 in 52 weeks. The price of TEVA stock has risen by 4.71% or $0.43 this year, reaching a new high 5 times. Still, the stock price is down -16.56% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TEVA stock investors should be aware that Teva Pharmaceutical Industries Limited (TEVA) stock had its last reported insider trading activity 8 days ago on Aug 07. On Aug 07, EVP, Chief Financial Officer Kalif Eliyahu Sharon sold 35,125 shares at $9.73 each. This transaction resulted in the insider making $341,889. On Aug 04, Weiss Amir sold 1,981 shares at a price of US$9.92. After the transaction, the insider now owns 42,442 shares. Hughes Eric A had earlier sold 52,742 shares on Aug 01 for $8.30 a share. The transaction was completed for $437,690.
Valuation Metrics
Beta for the stock is 1.16. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.71, the price-to-book (PB) ratio of 1.52, and the price-to-cash flow ratio of 9.12.
Company paid $0.0850 per share in dividends, remained unchanged from $0.0850 last year.
Financial Health
For the three months ended June 29, Teva Pharmaceutical Industries Limited’s quick ratio was 0.70, while its current ratio was 1.00, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 2.65, and the total debt to equity ratio is 2.93. As far as profitability goes, gross margin for the trailing twelve months is 49.10% percent. Teva Pharmaceutical Industries Limited’s EBITDA margin for the year ended June 29 was 26.73%, whereas its operating margin stood at -7.20% for the same period. Based on annual data, it had gross profit of $6.97 billion and revenue of $14.93 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TEVA’s return on assets (ROA) during the last 12 months has been -5.10%. There was a -5.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -28.30%.
Earnings Surprise
According to Teva Pharmaceutical Industries Limited’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $3.88 billion, while revenues rose by 2.37% to $3.66 billion. It was predicted that Teva Pharmaceutical Industries Limited’s quarterly earnings would be $0.56, but it ended up being $0.52, beating the consensus by 7.70%. EBITDA was -$346.0 million for the quarter. At the end of Teva Pharmaceutical Industries Limited’s most recent quarter ended June 29, its liabilities totaled 35.39 billion, while its total debt was $21.02 billion. Equity owned by shareholders amounts to $1.12 billion.
Technical Picture
Here’s a quick look at Teva Pharmaceutical Industries Limited’s (TEVA) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 63.05%, suggesting the stock is Neutral, with a 61.25% historical volatility rate.
The stochastic %K and %D were 81.23% and 82.85% respectively, while the average true range (ATR) was 0.32. Based on the 14-day stochastic reading of 75.07%, the RSI (14) reading is 64.95%. On the 9-day MACD Oscillator, the stock is at 0.03, and the 14-day reading is at 0.46.
Analyst Ratings
In its most recent analyst report, UBS raised its rating on Teva Pharmaceutical Industries Limited (NYSE: TEVA) to a Neutral. Prior to this, analysts firm rated the stock as a Sell. Analysts have assigned Teva Pharmaceutical Industries Limited (TEVA) an Hold rating. TEVA is a stock that is recommended for selling by 2 brokerage firms, while 8 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 3 others recommend it as a buy.
What is TEVA’s price target for the next 12 months?
The current consensus forecast for the stock is between $8.00 and $14.00, with a median target price of $10.00. In analyzing these forecasts, the average price target given by analysts for Teva Pharmaceutical Industries Limited (TEVA) is $10.25.
